Informações:
Falhas:
ID
23707
Descrição
Erlotinib and Sequential Positron Emission Tomography (PET) in Advanced Non Small Cell Lung Cancer (NSCLC); ODM derived from: https://clinicaltrials.gov/show/NCT00568841
Link
https://clinicaltrials.gov/show/NCT00568841
Palavras-chave
Versões (2)
- 11/07/2017 11/07/2017 -
- 11/07/2017 11/07/2017 -
Transferido a
11 de julho de 2017
DOI
Para um pedido faça login.
Licença
Creative Commons BY 4.0
Comentários do modelo :
Aqui pode comentar o modelo. Pode comentá-lo especificamente através dos balões de texto nos grupos de itens e itens.
Comentários do grupo de itens para :
Comentários do item para :
Para descarregar formulários, precisa de ter uma sessão iniciada. Por favor faça login ou registe-se gratuitamente.
Eligibility Carcinoma, Non-Small-Cell Lung NCT00568841
Eligibility Carcinoma, Non-Small-Cell Lung NCT00568841
- StudyEvent: Eligibility
Similar models
Eligibility Carcinoma, Non-Small-Cell Lung NCT00568841
- StudyEvent: Eligibility
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de dados
Alias
Informed Consent
Item
written informed consent
boolean
C0021430 (UMLS CUI [1])
Age
Item
≥ 18 years of age
boolean
C0001779 (UMLS CUI [1])
Non-Small Cell Lung Carcinoma untreated TNM clinical staging
Item
untreated non-small-cell lung cancer stage iiib/iv
boolean
C0007131 (UMLS CUI [1,1])
C0332155 (UMLS CUI [1,2])
C3258246 (UMLS CUI [1,3])
C0332155 (UMLS CUI [1,2])
C3258246 (UMLS CUI [1,3])
Life Expectancy
Item
life expectancy > 3 months
boolean
C0023671 (UMLS CUI [1])
ECOG performance status
Item
performance status ecog 0-2
boolean
C1520224 (UMLS CUI [1])
Immunotherapy Systemic | Chemotherapy | Antineoplastic Agents
Item
concurrent systemic immune therapy, chemotherapy or therapy with any anticancer drug not indicated in the study protocol
boolean
C0021083 (UMLS CUI [1,1])
C0205373 (UMLS CUI [1,2])
C0392920 (UMLS CUI [2])
C0003392 (UMLS CUI [3])
C0205373 (UMLS CUI [1,2])
C0392920 (UMLS CUI [2])
C0003392 (UMLS CUI [3])
Investigational New Drugs
Item
any investigational agent(s) within 4 weeks prior to study entry
boolean
C0013230 (UMLS CUI [1])
Targeted Therapy Epidermal Growth Factor Receptor | Antibodies | Small Molecule
Item
previous administration of any egfr-targeted therapy (antibodies, small molecules and others)
boolean
C2985566 (UMLS CUI [1,1])
C0034802 (UMLS CUI [1,2])
C3495458 (UMLS CUI [2])
C1328819 (UMLS CUI [3])
C0034802 (UMLS CUI [1,2])
C3495458 (UMLS CUI [2])
C1328819 (UMLS CUI [3])
Medical condition Excludes Clinical Trial Completion | Medical condition Preventing Comprehension Patient Information | Mental disorder Excludes Clinical Trial Completion | Mental disorder Preventing Comprehension Patient Information
Item
any medical, mental or psychological condition which in the opinion of the investigator would not permit the patient to complete the study or understand the patient information
boolean
C3843040 (UMLS CUI [1,1])
C0332196 (UMLS CUI [1,2])
C0008976 (UMLS CUI [1,3])
C0205197 (UMLS CUI [1,4])
C3843040 (UMLS CUI [2,1])
C1292733 (UMLS CUI [2,2])
C0162340 (UMLS CUI [2,3])
C1955348 (UMLS CUI [2,4])
C0004936 (UMLS CUI [3,1])
C0332196 (UMLS CUI [3,2])
C0008976 (UMLS CUI [3,3])
C0205197 (UMLS CUI [3,4])
C0004936 (UMLS CUI [4,1])
C1292733 (UMLS CUI [4,2])
C0162340 (UMLS CUI [4,3])
C1955348 (UMLS CUI [4,4])
C0332196 (UMLS CUI [1,2])
C0008976 (UMLS CUI [1,3])
C0205197 (UMLS CUI [1,4])
C3843040 (UMLS CUI [2,1])
C1292733 (UMLS CUI [2,2])
C0162340 (UMLS CUI [2,3])
C1955348 (UMLS CUI [2,4])
C0004936 (UMLS CUI [3,1])
C0332196 (UMLS CUI [3,2])
C0008976 (UMLS CUI [3,3])
C0205197 (UMLS CUI [3,4])
C0004936 (UMLS CUI [4,1])
C1292733 (UMLS CUI [4,2])
C0162340 (UMLS CUI [4,3])
C1955348 (UMLS CUI [4,4])